Loading...
•
Jun 30, 2022
Exelixis Q2 2022 Earnings Report
Exelixis reported strong commercial performance for CABOMETYX and advancements in pipeline activities.
Key Takeaways
Exelixis announced its second quarter 2022 financial results with total revenues of $419.4 million and GAAP diluted EPS of $0.22. The company highlighted the 22 percent growth in cabozantinib franchise net product revenues year-over-year and key cabozantinib milestones.
Total revenues for the quarter ended June 30, 2022 were $419.4 million.
GAAP net income for the quarter ended June 30, 2022 was $70.7 million, or $0.22 per share, basic and diluted.
Non-GAAP net income for the quarter ended June 30, 2022 was $89.7 million, or $0.28 per share, basic and diluted.
Cash, cash equivalents, restricted cash equivalents and investments were $2.0 billion at June 30, 2022.
Revenue by Segment
Forward Guidance
Exelixis is maintaining the following previously provided financial guidance for fiscal year 2022:
Positive Outlook
- Total revenues $1.525 billion - $1.625 billion
- Net product revenues $1.325 billion - $1.425 billion
- Cost of goods sold 5% - 6% of net product revenues
- Research and development expenses $725 million - $775 million
- Selling, general and administrative expenses $400 million - $450 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...